

Res. Asst. MUSTAFA ÇAKIR

Personal Information

Email: mustafacakir@erciyes.edu.tr

Web: <https://avesis.erciyes.edu.tr/mustafacakir/>

International Researcher IDs

ORCID: 0000-0002-8861-5485

Education Information

Undergraduate, Anadolu University, Faculty Of Science, Biyoloji, Turkey 2005 - 2010

Research Areas

Health Sciences, Medicine, Fundamental Medical Sciences, Medical Biology, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Research Assistant, Erciyes University, Tıp Fakültesi, Temel Bilimler, 2014 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells**
EKEN A., YETKİN M. F., VURAL A., Okus F. Z., Erdem S., Azizoglu Z. B., Haliloglu Y., Cakir M., Turkoglu E. M., Kilic Ö., et al.
FRONTIERS IN IMMUNOLOGY, vol.10, 2019 (SCI-Expanded)
- II. **The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer**
Sakalar C., Izgi K., Iskender B., Sezen S., Aksu H., ÇAKIR M., KURT B., Turan A., CANATAN H.
TUMOR BIOLOGY, vol.37, no.4, pp.4467-4477, 2016 (SCI-Expanded)
- III. **Myrtucommulone-A Induces both Extrinsic and Intrinsic Apoptotic Pathways in Cancer Cells**
Izgi K., ISKENDER B., JAUCH J., Sezen S., ÇAKIR M., CHARPENTIER M., CANATAN H., Sakalar C.
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, vol.29, no.9, pp.432-439, 2015 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

- I. **S1P1 receptor antagonists Fingolimod and SEW2871 affect human group 1 and 3 innate lymphoid cell biology**
EKEN A., YETKİN M. F., VURAL A., Okuş F. Z., CANATAN H., ALTUNTAŞ H., MİRZA M., ÇAKIR M., Erdem Ş.
ECTRIMS 2018 – 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.762

- II. **S1P(1) receptor antagonists Fingolimod and SEW2871 affect human group 1 and 3 innate lymphoid cell biology**
EKEN A., YETKİN M. F., Okus F. Z., Erdem S., ÇAKIR M., Kutuk M. S., VURAL A., KARA I., ALTUNTAŞ H., MİRZA M., et al.
34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Berlin, Germany, 10 - 12 October 2018, vol.24, pp.395
- III. **Fingolimod impacts innate lymphoid cell biology**
EKEN A., YETKİN M. F., Okuş F. Z., Erdem Ş., ÇAKIR M., VURAL A., ALTUNTAŞ H., MİRZA M., CANATAN H.
The Journal of Immunology, Teksas, United States Of America, 4 - 08 May 2018, vol.200
- IV. **Fingolimod impacts innate lymphoid cell biology**
EKEN A., YETKİN M. F., Okus F. Z., Erdem S., ÇAKIR M., VURAL A., Donmez-Altuntas H., MİRZA M., CANATAN H.
Annual Meeting of the American-Association-of-Immunologists (AAI), Texas, United States Of America, 4 - 08 May 2018, vol.200
- V. **Fingolimod ve SEW2871 insan Th17 hücresi gelişimini etkilemektedir**
YETKİN M. F., EKEN A., Okuş F., ÇAKIR M., ÖZDARENDELİ A., ALTUNTAŞ H., MİRZA M., CANATAN H.
10.Klinik Nöroimmunoloji Sempozyumu, Girne, Cyprus (Kktc), 1 - 05 April 2018, pp.34
- VI. **Sphingosine 1 phosphate 1 receptor agonists Fingolimod and SEW2871 impact innate lymphoid cell biology.**
EKEN A., YETKİN M. F., Okuş F. Z., Erdem S., ÇAKIR M., KÜTÜK M. S., ALTUNTAŞ H., MİRZA M., CANATAN H.
The World Immune Regulation Meeting XII (WIRM XII) kongresi, Davos, Switzerland, 14 - 17 March 2018, pp.46
- VII. **S1P1 Agonist SEW2871 Inhibits human Th17 cell generation and functions**
EKEN A., Okus F. Z., YETKİN M. F., ÇAKIR M., ÖZDARENDELİ A., MİRZA M.
IMMUNOLOGY2017, Washington Dc, United States Of America, 12 - 16 May 2017, vol.198
- VIII. **Direct and indirect effects of S1P1 Agonist SEW2871 on human Th17 cell generation and functions**
EKEN A., Okuş F., YETKİN M. F., ÇAKIR M., ÖZDARENDELİ A., ALTUNTAŞ H., MİRZA M., CANATAN H.
Erciyes Tıp Genetik Günleri, Kayseri, Turkey, 11 - 15 May 2017
- IX. **S1P1 Agonisti SEW2871'in insan Th17 hücresi gelişim ve fonksiyonlarını doğrudan ve dolaylı etkilemektedir**
EKEN A., Okuş F., YETKİN M. F., ÇAKIR M., ÖZDARENDELİ A., ALTUNTAŞ H., MİRZA M., CANATAN H.
XXIV. Ulusal İmmunoloji Kongresi, İstanbul, Turkey, 27 - 30 April 2017
- X. **Cytokine secretion by peripheral blood mononuclear cells in patients with axiasl spondyloarthritis and the effect of thymoquinone on cytokine profile**
KILIÇ E., ŞAKALAR Ç., AKSU H., ÇAKIR M., KILIÇ G., ÖZGÖÇMEN S.
American College of Rheumatology Annual Meeting ACR2015, San Francisco, United States Of America, 6 - 11 November 2015, vol.67, pp.1-2
- XI. **Production of a monoclonal antibody specific for AMHR2 for the use in ovarian cancer immunotherapy**
Turan A., ŞAKALAR Ç., KAYA S., Aksu H., ÇAKIR M., KURT B., SEZEN S., CANATAN H.
EACR-sponsored 3rd Anticancer Agent Development Congress, İzmir, Turkey, 18 - 19 May 2015, pp.75
- XII. **The Combination of Thymoquinone and Paclitaxel shows anti-tumor activity both in vitro and in vivo through the modulation of genes involved in apoptosis, cell cycle, tumor suppression and growth factor-cytokine activity**
ŞAKALAR Ç., İZGİ K., İSKENDER İZGİ B., Turan A., SEZEN S., Aksu H., ÇAKIR M., KURT B., CANATAN H.
EACR-sponsored 3rd Anticancer Agent Development Congress, İzmir, Turkey, 18 - 19 May 2015, pp.43

Metrics

Publication: 18

Citation (WoS): 80

Citation (Scopus): 102

H-Index (WoS): 3

H-Index (Scopus): 3